Published in Can Med Assoc J on April 01, 1982
Trifluoperazine-induced angioedema. Case Rep Psychiatry (2014) 0.75
Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry (1980) 1.43
Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry (1974) 1.09
Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatry (1979) 1.07
Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurol Scand (1974) 0.92
Early onset of tardive dyskinesia: case report. Am J Psychiatry (1979) 0.89
Neuroleptic-induced tardiave dyskinesias in nonpsychotic patients. Arch Neurol (1974) 0.87
Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry (1979) 0.86
Dopaminergic supersensitivity: influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia. Psychopharmacology (Berl) (1979) 0.83
Perioperative ischaemia in aortic surgery: combined epidural/general anaesthesia and epidural analgesia vs general anaesthesia and i.v. analgesia. Can J Anaesth (1996) 3.24
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry (1997) 2.65
Crystal structure of a fibrillarin homologue from Methanococcus jannaschii, a hyperthermophile, at 1.6 A resolution. EMBO J (2000) 2.20
Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry (1990) 2.12
International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev (1999) 1.74
Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry (1995) 1.59
Tardive dyskinesia: legal and preventive aspects. Can J Psychiatry (1990) 1.47
Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol (1991) 1.46
Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry (1993) 1.40
Interaction between caffeine and clozapine. J Clin Psychopharmacol (1994) 1.39
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry (1984) 1.37
Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A (1994) 1.30
Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol (2000) 1.27
A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol (1994) 1.19
Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry (1978) 1.19
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry (1985) 1.17
Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. JAMA (1999) 1.10
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry (1980) 1.09
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry (1995) 1.08
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci (1995) 1.07
Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule. Can Med Assoc J (1978) 1.07
Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatry (1979) 1.07
Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl) (1982) 1.05
A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl (1990) 1.05
Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis (1982) 1.04
Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther (1994) 1.02
Schizophreniform psychosis associated with chronic industrial toluene exposure: case report. J Clin Psychiatry (1985) 1.00
Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol (1999) 0.99
Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry (1993) 0.99
Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature (1984) 0.98
Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry (1998) 0.97
Schizophrenia as dopamine-deficiency disease. Lancet (1978) 0.96
Adult epiglottitis in a Canadian setting. Laryngoscope (1998) 0.95
Cortical porosis under plates. Reaction to unloading or to necrosis? J Bone Joint Surg Am (1994) 0.94
Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry (1999) 0.94
CCK in animal and human research on anxiety. Trends Pharmacol Sci (1993) 0.94
Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol (2000) 0.93
Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety (2012) 0.91
Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology (1999) 0.91
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatr Scand (1979) 0.91
The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry (1995) 0.90
Effects of five insecticides used in apple orchards on Hyaliodes vitripennis (Say) (Hemiptera: Miridae). J Environ Sci Health B (2000) 0.90
A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and radiological findings. J Neurosurg (1984) 0.90
A guide to benzodiazepine selection. Part I: Pharmacological aspects. Can J Psychiatry (1990) 0.89
Early onset of tardive dyskinesia: case report. Am J Psychiatry (1979) 0.89
Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci (1997) 0.89
Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry (1999) 0.89
Cutaneous vasculitis induced by paroxetine. Am J Psychiatry (2001) 0.89
Phenothiazine-induced ECG abnormalities: effect of a glucose load. Arch Gen Psychiatry (1977) 0.88
Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings. Neurosurgery (1985) 0.88
Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci (1997) 0.88
A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol (1995) 0.88
Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety (1998) 0.87
Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol (1990) 0.87
The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry (1998) 0.87
Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry (1979) 0.86
Effects of photoradiation therapy on normal rat brain. Neurosurgery (1984) 0.86
New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.86
Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol (1991) 0.85
Neurobiology of panic disorder. J Psychosom Res (1998) 0.84
A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) (1992) 0.84
Factors related to tardive dyskinesia. Am J Psychiatry (1979) 0.84
A case of mania associated with tomoxetine. Am J Psychiatry (1985) 0.84
Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry (1989) 0.83
Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'? Int Clin Psychopharmacol (2002) 0.83
Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry Neurosci (1991) 0.83
Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J Clin Psychopharmacol (1987) 0.83
A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry (1985) 0.83
Treatment of recurrent unipolar major depression with captopril. Biol Psychiatry (1988) 0.82
A simple and disposable sweat collector. Eur J Appl Physiol Occup Physiol (1991) 0.82
Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry (1996) 0.82
Photoradiation therapy: current status and applications in the treatment of brain tumors. Surg Neurol (1986) 0.82
A five year follow-up study of tardive dyskinesia. Psychopharmacol Bull (1986) 0.82
A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 2: Pathological findings. J Neurosurg (1984) 0.81
Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry (1983) 0.81
Efficacy and withdrawal of two potent benzodiazepines: bromazepam and lorazepam. Psychopharmacol Bull (1985) 0.81
Olanzapine-induced somnambulism. Am J Psychiatry (2001) 0.81
A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry (1983) 0.80
The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. J Psychosom Res (2001) 0.80
Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. Am J Med Genet (1994) 0.80
[Iatrogenic psychiatric-like symptoms recognition]. Encephale (2010) 0.80
Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. Br J Clin Pharmacol (1987) 0.80
Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine. J Clin Psychopharmacol (1998) 0.80
Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol (1994) 0.80
Articulatory impairment associated with tardive dyskinesia. J Nerv Ment Dis (1990) 0.80
Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci (1997) 0.79
Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.79
Doppler sonographic studies on the ophthalmic and central retinal arteries in the gravid woman. J Ultrasound Med (1995) 0.79
Lithium and regression of oat-cell carcinoma. Can Med Assoc J (1981) 0.79
CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol (1999) 0.79
Fluoxetine in the treatment of obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.79
Development of a sensitive and specific assay system for cholecystokinin tetrapeptide. Peptides (1997) 0.79
High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry (1982) 0.79
Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry (1992) 0.79
Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol (1983) 0.79
Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci (1992) 0.79
Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull (1986) 0.79